LivaNova Launches Next Generation ICD and CRT-D Devices in the United States

LONDON, LivaNova PLC a market-leading medical technology company, announced today the launch of PLATINIUM, its next-generation range of implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds).  PLATINIUM models offer unmatched longevity¹ thanks to LivaNova’s breakthrough technology and optimized manufacturing processes which ensure extremely low energy consumption. The service life is projected to last over 14 years for the single-chamber ICD, over 13 years for the dual-chamber ICD and over 10 years for CRT-D devices.

“Increasing the longevity of ICD and CRT-D devices is crucial for patients to avoid early replacement surgeries, which carry risks of complications and increase the cost of care,” said Dr. Steven Kutalek, M.D., FACC, FHRS, Drexel University College of Medicine, Philadelphia, PA.  “Longevity needs to be a primary consideration when selecting a device for a patient.  I welcome the launch of LivaNova’s PLATINIUM devices.  They represent a significant improvement in medical technology, combining superb arrhythmia detection and discrimination algorithms with excellent battery longevity.”

More than one third of patients implanted with an ICD or a CRT-D will require at least one replacement due to battery depletion.  Replacement procedures are associated with twice as many surgical re-interventions compared to initial implant surgeries due to increased rates of complications, such as infections.  The mortality rate in patients with infections reaches 16.9% at one year and 27.5% at three years⁴. 

The industry-leading longevity¹ of PLATINIUM has been achieved without compromising the size of the devices.  PLATINIUM devices range in size from 31cc to 33cc, and the Ergoform^TM design of the can, with its rounded shape and smooth edges is designed to facilitate implant procedures and improve patient comfort.  PLATINIUM devices also feature proven therapeutic functions such as PARAD+^TM, a best-in-class arrhythmia discrimination algorithm, and SafeR^TM, a pacing mode which preserves natural heart conduction.

“The technology we have developed will provide U.S. physicians and patients a broader range of devices offering the longest projected longevity of any on the market,” said Benoît Clinchamps, LivaNova, Vice President, General Manager CRM.  “PLATINIUM addresses the medical community requests in closing the gap between patient life expectancy and device service life.  LivaNova is committed to health innovation that matters and PLATINIUM devices reaffirm this commitment.”

Source: LivaNova